Dr Tyrone S Cushing, MD | |
575 Chestnut St, Newton, MA 02468-1225 | |
(617) 244-1418 | |
Not Available |
Full Name | Dr Tyrone S Cushing |
---|---|
Gender | Male |
Speciality | General Practice |
Location | 575 Chestnut St, Newton, Massachusetts |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1326147869 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 39666 (Massachusetts) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Tyrone S Cushing, MD 575 Chestnut St, Newton, MA 02468-1225 Ph: (617) 244-1418 | Dr Tyrone S Cushing, MD 575 Chestnut St, Newton, MA 02468-1225 Ph: (617) 244-1418 |
News Archive
Bristol-Myers Squibb Company and AstraZeneca today announced results from a randomized, double-blind Phase 3 clinical study in adults with type 2 diabetes inadequately controlled on metformin therapy alone.
Neuralstem, Inc. announced that its spinal cord stem cells survived in rat brains affected by stroke and differentiated predominantly into neurons. The transplanted animals showed significant improvement in some motor skill and strength measurements. The study entitled, "Intracerebral Implantation of Adherent Human Neural Stem Cells To Reverse Motor Deficits in Chronic Stroke Rats," was presented earlier today by senior study author, Dr. Shinn-Zong Lin, M.D., Ph.D., at the Stem Cells USA & Regenerative Medicine Conference
The Multiple Myeloma Research Foundation (MMRF) announced today that it has received a 4-star rating from Charity Navigator, America's largest independent evaluator of charitable donations, for demonstrating exceptional fiscal responsibility in its efforts to bring patients the next generation of treatments and find a cure for multiple myeloma. This is the seventh consecutive year the MMRF has been honored with this distinguished recognition.
Researchers at Brown University have found that the length of an average Medicare-certified hospice stay in a nursing home has doubled during the last 10 years. The study, which will appear in the August issue of The Journal of the American Geriatrics Society, evaluated hospice use in U.S. nursing homes between 1999 and 2006. It found the typical treatment time has increased from 46 to 93 days. The researchers cited a standard daily payment rate for most Medicare hospice enrollment days as an incentive for some of the longer stays.
› Verified 8 days ago